Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (286)	8/31/1999 12:15:00 AM
From: Ben Wa	Respond to of 666

Prudential was quoted all over 'da place - their eehh, technical biotechnical technicial analist Ralph Kramdon said to buy it.

To: kendall harmon who wrote (286)	8/31/1999 12:44:00 AM
From: Bharat H. Barai	Read Replies (2) \| Respond to of 666

Most people forget that once a drug is approved for one indication, the physicians can legally use the drug for any other indication and in a different dose, as long as there is scientific basis to support such use. Rituxan is used lot more for indications other than in package insert. Bexaar may seek approval for a very limited indication, to get thru quickly. Then let MDs use it for other indications. All pharmaceutical companies play this legal game to avoid Billions of Dollars in additional FDA related expenses. Lilly got Gemcitabine approved for Pancreatic Cancer, the drug is used mostly for Lung Cancer, Lymphomas etc. BMY got Etoposide approved for refractory Testicular Cancer and the drug is used 99% for other indications. Taxol was originally approved for refractory Ovarian Cancer and most use today is in Breast and Lung Cancers. So Off label uses are norms rather than exception in Oncology. Bexaar appears to be far more effective than Rituxan, needs only 3 doses but will probably be administered in Hospital, because of radio active compound handling. Rituxan is used today more and more as 1st line therapy, with chemotherapy for low grade as well as high grade lymphomas. Some have started using Rituxan for refractory Hodgkin's also. If the response rates are as good as in pivotal trial, Bexaar will be a Drug Royale for treatment of Lymphomas. Bharat H. Barai MD Hematologist-Oncologist

To: kendall harmon who wrote (286)	8/31/1999 1:08:00 AM
From: Vector1	Respond to of 666

Kendall, I do not know where the stock will settle in. My guess is low 20s. It may even hit the high teen for a while. Yes I agree the Essinger article was not fair but the fact is the shorts were right on the filing not being accepted (even if for the wrong reason). It is their day in the sun. One problem is for the company is that its credibility has taken a beating. That makes it open season for rumor and inuendo. The only way to have it stop is to have the filing accepted, show great results at the ASH conference in December and have a unanimous rec from the biologics committee. Until then preditors will attack at will. V1